BRPI0811198B8 - fosfatase alcalina direcionada a osso, kits e métodos de seu uso - Google Patents

fosfatase alcalina direcionada a osso, kits e métodos de seu uso

Info

Publication number
BRPI0811198B8
BRPI0811198B8 BRPI0811198A BRPI0811198A BRPI0811198B8 BR PI0811198 B8 BRPI0811198 B8 BR PI0811198B8 BR PI0811198 A BRPI0811198 A BR PI0811198A BR PI0811198 A BRPI0811198 A BR PI0811198A BR PI0811198 B8 BRPI0811198 B8 BR PI0811198B8
Authority
BR
Brazil
Prior art keywords
amino acid
alkaline phosphatase
kits
bone
methods
Prior art date
Application number
BRPI0811198A
Other languages
English (en)
Portuguese (pt)
Inventor
Boileau Guy
Landy Hal
Lemire Isabelle
Crine Philippe
Leonard Pierre
Heft Robert
P Loisel Thomas
Original Assignee
Alexion Holding B V
Alexion Pharma Gmbh
Alexion Pharma Holding Unlimited Company
Alexion Pharma Int Sarl
Alexion Pharma Inc
Enobia Canada Lp
Enobia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Holding B V, Alexion Pharma Gmbh, Alexion Pharma Holding Unlimited Company, Alexion Pharma Int Sarl, Alexion Pharma Inc, Enobia Canada Lp, Enobia Pharma Inc filed Critical Alexion Holding B V
Priority to BR122019000505-2A priority Critical patent/BR122019000505B1/pt
Publication of BRPI0811198A2 publication Critical patent/BRPI0811198A2/pt
Publication of BRPI0811198A8 publication Critical patent/BRPI0811198A8/pt
Publication of BRPI0811198B1 publication Critical patent/BRPI0811198B1/pt
Publication of BRPI0811198B8 publication Critical patent/BRPI0811198B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
BRPI0811198A 2007-05-11 2008-05-12 fosfatase alcalina direcionada a osso, kits e métodos de seu uso BRPI0811198B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019000505-2A BR122019000505B1 (pt) 2007-05-11 2008-05-12 Fosfatase alcalina direcionada ao osso, kits e métodos de seu uso

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
US60/917,589 2007-05-11
PCT/CA2008/000923 WO2008138131A1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Publications (4)

Publication Number Publication Date
BRPI0811198A2 BRPI0811198A2 (pt) 2014-10-21
BRPI0811198A8 BRPI0811198A8 (pt) 2018-08-14
BRPI0811198B1 BRPI0811198B1 (pt) 2021-03-09
BRPI0811198B8 true BRPI0811198B8 (pt) 2021-05-25

Family

ID=40001639

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0811198A BRPI0811198B8 (pt) 2007-05-11 2008-05-12 fosfatase alcalina direcionada a osso, kits e métodos de seu uso
BR122019000505-2A BR122019000505B1 (pt) 2007-05-11 2008-05-12 Fosfatase alcalina direcionada ao osso, kits e métodos de seu uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019000505-2A BR122019000505B1 (pt) 2007-05-11 2008-05-12 Fosfatase alcalina direcionada ao osso, kits e métodos de seu uso

Country Status (25)

Country Link
US (1) US20100297119A1 (enExample)
EP (3) EP2662448B1 (enExample)
JP (1) JP5732603B2 (enExample)
AT (1) ATE536413T1 (enExample)
AU (1) AU2008250945B2 (enExample)
BR (2) BRPI0811198B8 (enExample)
CA (1) CA2687001C (enExample)
CY (1) CY2016005I1 (enExample)
DE (1) DE202008018131U1 (enExample)
DK (3) DK2158319T3 (enExample)
ES (3) ES2380546T3 (enExample)
FR (1) FR16C0007I2 (enExample)
HR (1) HRP20140416T1 (enExample)
HU (2) HUE031655T2 (enExample)
IL (1) IL202057A0 (enExample)
LT (1) LTC2368999I2 (enExample)
LU (1) LU92976I2 (enExample)
ME (1) ME01828B (enExample)
NL (1) NL300798I1 (enExample)
NO (1) NO2016002I2 (enExample)
PL (3) PL2158319T4 (enExample)
PT (3) PT2368999E (enExample)
RS (1) RS53302B (enExample)
SI (2) SI2662448T1 (enExample)
WO (1) WO2008138131A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055861T2 (hu) * 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
EP2185589B1 (en) 2007-06-01 2016-01-06 University of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
AU2011245005A1 (en) * 2010-04-30 2012-11-22 Alexion Pharma Holding Methods, compositions, and kits for the treatment of matrix mineralization disorders
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) * 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014031646A2 (en) 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
PL3097189T3 (pl) 2014-01-24 2018-11-30 Am-Pharma B.V. Chimeryczne białka podobne do alkalicznej fosfatazy
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
MX394116B (es) 2015-07-24 2025-03-19 Gliknik Inc Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada.
RU2745528C2 (ru) * 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (en) * 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
JP7613826B2 (ja) * 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
WO2018004517A1 (en) 2016-06-27 2018-01-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
AU2017371182B2 (en) 2016-12-09 2024-03-28 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
WO2018164995A1 (en) * 2017-03-09 2018-09-13 Alexion Pharmaceuticals, Inc . Glycoprotein manufacturing process
CA3057502A1 (en) * 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
JP2021519590A (ja) * 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
CA3137045A1 (en) 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Alkaline phosphate-based oncology treatments
US12433938B2 (en) * 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12478662B2 (en) 2020-01-03 2025-11-25 The United States of America as represented by the Secretary Department of Heath and Human Services TNAP locally administered for promoting periodontal health
WO2022051555A2 (en) * 2020-09-03 2022-03-10 Rampart Bioscience, Inc. Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CA3263089A1 (en) * 2022-08-31 2024-03-07 Univ Utah Res Found GJA1-20K COMPOSITIONS AND METHODS FOR MITIGATING ISCHEMIC-REPERFUSION INJURY

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ES2284545T3 (es) 1999-11-16 2007-11-16 Genzyme Corporation Vectores y transgenes con elementos reguladores para la administracion de genes del higado.
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
BRPI0512496A (pt) 2004-06-23 2008-03-04 Genzyme Corp processos e composições para o tratamento de doenças policìsticas
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
JP2008521575A (ja) 2004-12-01 2008-06-26 ジェンザイム・コーポレイション 肝臓を標的とした遺伝物質の送達方法

Also Published As

Publication number Publication date
HK1162589A1 (en) 2012-08-31
IL202057A0 (en) 2011-08-01
BR122019000505B1 (pt) 2022-01-18
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
PL2368999T3 (pl) 2014-08-29
BRPI0811198A2 (pt) 2014-10-21
CY2016005I2 (el) 2016-08-31
NL300798I2 (enExample) 2016-03-16
BRPI0811198B1 (pt) 2021-03-09
DE202008018131U1 (de) 2011-12-30
CA2687001A1 (en) 2008-11-20
HK1141047A1 (en) 2010-10-29
PL2662448T3 (pl) 2017-07-31
EP2368999A1 (en) 2011-09-28
NO2016002I1 (no) 2016-02-02
RS53302B (sr) 2014-08-29
DK2368999T3 (da) 2014-05-26
SI2368999T1 (sl) 2014-07-31
WO2008138131A4 (en) 2008-12-31
NO2016002I2 (no) 2016-02-02
WO2008138131A9 (en) 2009-08-06
PL2158319T4 (pl) 2016-04-29
DK2158319T3 (da) 2012-03-19
ME01828B (me) 2014-12-20
NL300798I1 (enExample) 2016-03-16
EP2158319A1 (en) 2010-03-03
ES2471915T3 (es) 2014-06-27
HUS1600005I1 (hu) 2016-02-29
JP2010526543A (ja) 2010-08-05
FR16C0007I1 (enExample) 2016-04-15
HK1191372A1 (en) 2014-07-25
AU2008250945A1 (en) 2008-11-20
US20100297119A1 (en) 2010-11-25
LTPA2016004I1 (lt) 2016-02-25
EP2158319A4 (en) 2010-07-21
ES2380546T3 (es) 2012-05-16
BR122019000505A2 (pt) 2021-12-14
LU92976I2 (en) 2016-04-11
PL2158319T3 (pl) 2012-05-31
PT2662448T (pt) 2017-03-29
SI2662448T1 (sl) 2017-05-31
DK2662448T3 (en) 2017-03-20
EP2662448B1 (en) 2016-12-21
PT2158319E (pt) 2012-03-06
LTC2368999I2 (lt) 2017-09-25
EP2368999B1 (en) 2014-03-12
ES2619332T3 (es) 2017-06-26
WO2008138131A1 (en) 2008-11-20
PT2368999E (pt) 2014-05-26
AU2008250945A2 (en) 2009-12-24
CA2687001C (en) 2019-02-12
BRPI0811198A8 (pt) 2018-08-14
HRP20140416T1 (hr) 2014-06-20
AU2008250945B2 (en) 2013-12-12
CY2016005I1 (el) 2016-08-31
ATE536413T1 (de) 2011-12-15
JP5732603B2 (ja) 2015-06-10
FR16C0007I2 (fr) 2017-01-27
EP2158319B1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
BRPI0811198B8 (pt) fosfatase alcalina direcionada a osso, kits e métodos de seu uso
GT201000037A (es) Depsipéptidos cíclicos
BRPI0411528A (pt) uso de isomalte como prebiótico
TR200201887T2 (tr) Sulu elastomer kaplama bileşimi ve bununla kaplanmış cisimler.
BRPI0418513A (pt) prótese de ombro com base para fratura umeral
CR10303A (es) "derivados de quinolina y su uso com pesticidas"
UY30144A1 (es) Composiciones de ramnolipidos y metodos de uso relacionados
BRPI0907317A2 (pt) composição farmacêutica e método para fabricar uma composição farmacêutica tópica em gel, espuma e em spray
PA8781701A1 (es) Derivados de 7-alquinil-1,8- naftiridonas, su preparaciones y su aplicacion en terapeutica
BR112023021867A2 (pt) Composições de anticorpo anti-tslp e seus usos
SV2003000995A (es) Nuevas arilsulfonamidas como agentes antivirales ref. lea35214-sv
AR064219A1 (es) Cuerpo moldeado que contiene titanio
UY30552A1 (es) Combinaciones farmacologiicas en base a derivados sustituidos de la n-(5-{2-[1,1-dimetil-propilamino]-1-hidroxi-metil}-2-hidroxi-fenil)-metansulfonamida y aplicaciones
BRPI0603813A (pt) máquina de lavar automática com movimento de lavar toroidal e toroidal inverso
BRPI0416708A (pt) derivados de aminoquinazolidinadiona antibacterianos
UY31139A1 (es) Formas cristalinas de 3-(2r-tetrahidrofuril-metil)-2-tioxantina
GT200500250A (es) Hexadecasacaridos biotinilados, su preparacion y su utilizacion
BR112021022665A2 (pt) 12-oxaspiro [5,5] undec-8-eno úteis em composições de fragrância
BR112022006450A2 (pt) Artigo absorvente
TR202104290U5 (tr) Bi̇r su geçi̇rmez çorap
TR200606750U (tr) Pratik ayak bağlantı aparatı.
TR202104284U5 (tr) Üç boyutlu fi̇gür i̇çeren bi̇r sihhi̇ armatür yapilanmasi
TWD199035S (zh) 懸臂工作車主構件
BRMU8501826U (pt) disposição construtiva em argola para cortinas
TR200500400U (tr) Bağlantı seti

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ENOBIA CANADA LIMITED PARTNERSHIP (CA)

B25A Requested transfer of rights approved

Owner name: ALEXION PHARMA INTERNATIONAL SARL (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ALEXION PHARMA GMBH (CH)

B25A Requested transfer of rights approved

Owner name: ALEXION HOLDING B.V. (NL)

B25A Requested transfer of rights approved

Owner name: ALEXION PHARMA HOLDING UNLIMITED COMPANY (BM)

B25A Requested transfer of rights approved

Owner name: ALEXION PHARMACEUTICALS, INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/05/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF